# Amiodarone

Drug · id `cardio:amiodarone` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

Also called: Pacerone; Nexterone; Cordarone

Browse, organ or system: Heart  
Browse, condition area: Heart rhythm problems  

## In plain language

Amiodarone is an antiarrhythmic medicine. Its US labels describe two forms: tablets (Pacerone is a US brand) and an injection (Nexterone). The tablet label lists documented, life-threatening recurrent ventricular fibrillation and life-threatening recurrent hemodynamically unstable ventricular tachycardia in adults who have not responded to other available antiarrhythmics or cannot tolerate them. The injection label lists treatment and prophylaxis of frequently recurring ventricular fibrillation and hemodynamically unstable ventricular tachycardia in patients refractory to other therapy. The tablet label carries a boxed warning: the medicine is intended only for the indicated life-threatening arrhythmias because its use is accompanied by substantial toxicity, and it can cause lung toxicity, liver toxicity that can be fatal, and worse arrhythmias. Cordarone, the brand approved in 1985 under NDA018972, is listed as discontinued.

## Technical summary

RxNorm ingredient 703 (amiodarone); UNII 976728SY6Z is the UNII of the salt, amiodarone hydrochloride, that the labels give, so it is a broad match; US drug-label class Antiarrhythmic (established pharmacologic class, RxClass). Labels read: Pacerone tablets (Upsher-Smith, abbreviated application ANDA075135, effective 2025-07-14) and Nexterone injection (Baxter, NDA022325, effective 2024-04-16). Other openFDA amiodarone labels, from generic and repackager sponsors, were listed and not used. Cordarone tablets (Wyeth, NDA018972) are listed in Drugs@FDA with marketing status Discontinued; the original approval is dated 1985-12-24, classified as a Type 1 new molecular entity with priority review. The tablet indication sentence says "unstable tachycardia" without the word ventricular; the Highlights line of the same label names ventricular tachycardia. Neither label lists atrial fibrillation, atrial flutter or supraventricular tachycardia. This page records label statements and the class only: no trial result and no dose is recorded.

## Claims, with the population each applies to

## Context: United States approval record NDA018972 for Cordarone (amiodarone hydrochloride tablets)

Recipient: Recipient not specified; Population: Not stated in the fetched Drugs@FDA record. It names a product and a sponsor and gives no intended population or indication.; Care setting: Not stated in the FDA record; Geography: United States (decision by the US Food and Drug Administration); Life stage: Not stated in the FDA record; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (regulatory decision)

### The openFDA Drugs@FDA record for New Drug Application NDA018972 names WYETH PHARMS as sponsor and lists one product, CORDARONE tablets (amiodarone hydrochloride), with marketing status Discontinued. It lists the original approval as submission ORIG-1, with status date 24 December 1985, classified as Type 1 - New Molecular Entity, with priority review.

- Category: Regulatory
- Evidence stage: Evidence stage not applicable
- Certainty: Certainty not assessed
- Applies to: Recipient: Recipient not specified; Population: Not stated in the fetched Drugs@FDA record. It names a product and a sponsor and gives no intended population or indication.; Care setting: Not stated in the FDA record; Geography: United States (decision by the US Food and Drug Administration); Life stage: Not stated in the FDA record; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (regulatory decision)
- Limitations: This claim records the original approval and the status the record gives, as of the fetch date. The record carries no indication text for the original approval, so it does not say what the medicine was approved to treat in 1985. It lists many later supplements. A discontinued status says the product is not marketed under this application; it is not a finding about safety or effectiveness. An approval is not a finding about how well the medicine works. openFDA's own disclaimer says not to rely on it for decisions about medical care.
- Last checked: 2026-10-30
- Sources:
  1. Supports: openFDA Drugs@FDA record for NDA018972 (CORDARONE, amiodarone hydrochloride tablets) (Regulator, edition openFDA Drugs@FDA application record returned on 2026-10-30. It lists the original approval as submission ORIG-1, with an approval status date of 19851224, and one product, CORDARONE tablets, with marketing status Discontinued.) <https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA018972%22&limit=1>
     Locator: results\[0\].application\_number. Retrieved 2026-10-30T19:46:06Z. Source state: Current. Version fingerprint: 92c954cf9ed6c46ab0fafd51aff46801c841dfa1f05982f98d47d36ffe7d713d.
     How it applies: The application number of this record.
  2. Supports: openFDA Drugs@FDA record for NDA018972 (CORDARONE, amiodarone hydrochloride tablets) (Regulator, edition openFDA Drugs@FDA application record returned on 2026-10-30. It lists the original approval as submission ORIG-1, with an approval status date of 19851224, and one product, CORDARONE tablets, with marketing status Discontinued.) <https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA018972%22&limit=1>
     Locator: results\[0\].sponsor\_name. Retrieved 2026-10-30T19:46:06Z. Source state: Current. Version fingerprint: 92c954cf9ed6c46ab0fafd51aff46801c841dfa1f05982f98d47d36ffe7d713d.
     How it applies: The application sponsor, as the record writes the name.
  3. Supports: openFDA Drugs@FDA record for NDA018972 (CORDARONE, amiodarone hydrochloride tablets) (Regulator, edition openFDA Drugs@FDA application record returned on 2026-10-30. It lists the original approval as submission ORIG-1, with an approval status date of 19851224, and one product, CORDARONE tablets, with marketing status Discontinued.) <https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA018972%22&limit=1>
     Locator: results\[0\].products\[0\].brand\_name. Retrieved 2026-10-30T19:46:06Z. Source state: Current. Version fingerprint: 92c954cf9ed6c46ab0fafd51aff46801c841dfa1f05982f98d47d36ffe7d713d.
     How it applies: The product brand name.
  4. Supports: openFDA Drugs@FDA record for NDA018972 (CORDARONE, amiodarone hydrochloride tablets) (Regulator, edition openFDA Drugs@FDA application record returned on 2026-10-30. It lists the original approval as submission ORIG-1, with an approval status date of 19851224, and one product, CORDARONE tablets, with marketing status Discontinued.) <https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA018972%22&limit=1>
     Locator: results\[0\].products\[0\].marketing\_status. Retrieved 2026-10-30T19:46:06Z. Source state: Current. Version fingerprint: 92c954cf9ed6c46ab0fafd51aff46801c841dfa1f05982f98d47d36ffe7d713d.
     How it applies: The product marketing status.
  5. Supports: openFDA Drugs@FDA record for NDA018972 (CORDARONE, amiodarone hydrochloride tablets) (Regulator, edition openFDA Drugs@FDA application record returned on 2026-10-30. It lists the original approval as submission ORIG-1, with an approval status date of 19851224, and one product, CORDARONE tablets, with marketing status Discontinued.) <https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA018972%22&limit=1>
     Locator: results\[0\].submissions\[27\].submission\_type. Retrieved 2026-10-30T19:46:06Z. Source state: Current. Version fingerprint: 92c954cf9ed6c46ab0fafd51aff46801c841dfa1f05982f98d47d36ffe7d713d.
     How it applies: The original submission.
  6. Supports: openFDA Drugs@FDA record for NDA018972 (CORDARONE, amiodarone hydrochloride tablets) (Regulator, edition openFDA Drugs@FDA application record returned on 2026-10-30. It lists the original approval as submission ORIG-1, with an approval status date of 19851224, and one product, CORDARONE tablets, with marketing status Discontinued.) <https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA018972%22&limit=1>
     Locator: results\[0\].submissions\[27\].submission\_status\_date. Retrieved 2026-10-30T19:46:06Z. Source state: Current. Version fingerprint: 92c954cf9ed6c46ab0fafd51aff46801c841dfa1f05982f98d47d36ffe7d713d.
     How it applies: The original approval status date, in compact form.
  7. Supports: openFDA Drugs@FDA record for NDA018972 (CORDARONE, amiodarone hydrochloride tablets) (Regulator, edition openFDA Drugs@FDA application record returned on 2026-10-30. It lists the original approval as submission ORIG-1, with an approval status date of 19851224, and one product, CORDARONE tablets, with marketing status Discontinued.) <https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA018972%22&limit=1>
     Locator: results\[0\].submissions\[27\].submission\_class\_code\_description. Retrieved 2026-10-30T19:46:06Z. Source state: Current. Version fingerprint: 92c954cf9ed6c46ab0fafd51aff46801c841dfa1f05982f98d47d36ffe7d713d.
     How it applies: The submission classification of the original approval.
  8. Supports: openFDA Drugs@FDA record for NDA018972 (CORDARONE, amiodarone hydrochloride tablets) (Regulator, edition openFDA Drugs@FDA application record returned on 2026-10-30. It lists the original approval as submission ORIG-1, with an approval status date of 19851224, and one product, CORDARONE tablets, with marketing status Discontinued.) <https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA018972%22&limit=1>
     Locator: results\[0\].submissions\[27\].review\_priority. Retrieved 2026-10-30T19:46:06Z. Source state: Current. Version fingerprint: 92c954cf9ed6c46ab0fafd51aff46801c841dfa1f05982f98d47d36ffe7d713d.
     How it applies: The review priority of the original approval.

## Context: Patients refractory to other therapy for whom the US label of amiodarone injection (Nexterone) lists an indication: frequently recurring ventricular fibrillation or hemodynamically unstable ventricular tachycardia

Recipient: Recipient not specified; Population: Patients described in the indications section of the label. The label sentence gives no age range.; Care setting: Prescription medicine given as an injection, as described in the US label; Geography: United States (label of the US Food and Drug Administration); Life stage: Not stated in the label passage read; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (label statement)

### The US label of Nexterone (amiodarone injection, Baxter), in the version dated 16 April 2024 in openFDA, lists the injection for initiation of treatment and prophylaxis of frequently recurring ventricular fibrillation and hemodynamically unstable ventricular tachycardia in patients refractory to other therapy.

- Category: Description
- Evidence stage: Evidence stage not applicable
- Certainty: Certainty not assessed
- Applies to: Recipient: Recipient not specified; Population: Patients described in the indications section of the label. The label sentence gives no age range.; Care setting: Prescription medicine given as an injection, as described in the US label; Geography: United States (label of the US Food and Drug Administration); Life stage: Not stated in the label passage read; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (label statement)
- Limitations: This claim records what the label says it is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. Only the first indication sentence was read; the record has no boxed warning field, and warnings, doses and interactions were not read. Labels change, and openFDA lists other injection labels with other text. openFDA's own disclaimer says not to rely on it for decisions about medical care.
- Last checked: 2026-10-30
- Sources:
  1. Supports: openFDA drug label record for Nexterone (amiodarone injection), Baxter label: indications (Regulator, edition The openFDA drug label record for set id e9108958-b8d7-4fba-87c3-9a32990de551 (manufacturer Baxter Healthcare Corporation; NDA022325), returned on 2026-10-30. The label text is dated 2024-04-16 (effective\_time). A repackager label of Nexterone (HealthFirst, 2024-02-19) and the labels of other amiodarone injections were listed and not used. The record carries no boxed warning field.) <https://api.fda.gov/drug/label.json?search=set_id:%22e9108958-b8d7-4fba-87c3-9a32990de551%22&limit=1>
     Locator: results\[0\].indications\_and\_usage\[0\], 1, sentence 1, fragment 1 of 2. Retrieved 2026-10-30T19:46:55Z. Source state: Current. Version fingerprint: bb5fd04fceab84988417e394dd950279d8e65de001585c3bffe5b92e1c663231.
     How it applies: Indication, first part.
  2. Supports: openFDA drug label record for Nexterone (amiodarone injection), Baxter label: indications (Regulator, edition The openFDA drug label record for set id e9108958-b8d7-4fba-87c3-9a32990de551 (manufacturer Baxter Healthcare Corporation; NDA022325), returned on 2026-10-30. The label text is dated 2024-04-16 (effective\_time). A repackager label of Nexterone (HealthFirst, 2024-02-19) and the labels of other amiodarone injections were listed and not used. The record carries no boxed warning field.) <https://api.fda.gov/drug/label.json?search=set_id:%22e9108958-b8d7-4fba-87c3-9a32990de551%22&limit=1>
     Locator: results\[0\].indications\_and\_usage\[0\], 1, sentence 1, fragment 2 of 2. Retrieved 2026-10-30T19:46:55Z. Source state: Current. Version fingerprint: bb5fd04fceab84988417e394dd950279d8e65de001585c3bffe5b92e1c663231.
     How it applies: Indication, second part: ventricular tachycardia and prior therapy.
  3. Background: openFDA drug label record for Nexterone (amiodarone injection), Baxter label: indications (Regulator, edition The openFDA drug label record for set id e9108958-b8d7-4fba-87c3-9a32990de551 (manufacturer Baxter Healthcare Corporation; NDA022325), returned on 2026-10-30. The label text is dated 2024-04-16 (effective\_time). A repackager label of Nexterone (HealthFirst, 2024-02-19) and the labels of other amiodarone injections were listed and not used. The record carries no boxed warning field.) <https://api.fda.gov/drug/label.json?search=set_id:%22e9108958-b8d7-4fba-87c3-9a32990de551%22&limit=1>
     Locator: results\[0\].effective\_time. Retrieved 2026-10-30T19:46:55Z. Source state: Current. Version fingerprint: bb5fd04fceab84988417e394dd950279d8e65de001585c3bffe5b92e1c663231.
     How it applies: Effective date of the label text read, 20240416.

## Context: Adults for whom the US label of amiodarone tablets (Pacerone) lists an indication: life-threatening recurrent ventricular fibrillation or recurrent hemodynamically unstable ventricular tachycardia

Recipient: Adult; Population: Adults described in the indications section of the label; the indication sentence is written for adults.; Care setting: Prescription medicine in tablet form, as described in the US label; the boxed warning says to initiate it in a clinical setting where continuous electrocardiograms and cardiac resuscitation are available; Geography: United States (label of the US Food and Drug Administration); Life stage: Adults, as the label states; Follow-up: Not applicable (label statement)

### The US label of Pacerone (amiodarone hydrochloride tablets, Upsher-Smith), in the version dated 14 July 2025 in openFDA, lists the tablets for documented, life-threatening recurrent ventricular fibrillation and life-threatening recurrent hemodynamically unstable tachycardia in adults who have not responded to adequate doses of other available antiarrhythmics or when alternative agents cannot be tolerated. The Highlights lines of the label name recurrent ventricular fibrillation and recurrent hemodynamically unstable ventricular tachycardia. The label carries a boxed warning titled pulmonary, hepatic and cardiac toxicity. It says the medicine is intended for use only in patients with the indicated life-threatening arrhythmias because its use is accompanied by substantial toxicity, that it can cause pulmonary toxicity and liver toxicity that can be fatal, and that it can exacerbate arrhythmias.

- Category: Description
- Evidence stage: Evidence stage not applicable
- Certainty: Certainty not assessed
- Applies to: Recipient: Adult; Population: Adults described in the indications section of the label; the indication sentence is written for adults.; Care setting: Prescription medicine in tablet form, as described in the US label; the boxed warning says to initiate it in a clinical setting where continuous electrocardiograms and cardiac resuscitation are available; Geography: United States (label of the US Food and Drug Administration); Life stage: Adults, as the label states; Follow-up: Not applicable (label statement)
- Limitations: This claim records what the label says it is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. Only the indications, the main lines of the boxed warning and the first sentence on mechanism were read; contraindications, doses, interactions and other warnings were not recorded. The label sentence says "unstable tachycardia" without the word ventricular; the ventricular wording is in the Highlights line. Labels change: openFDA also lists repackager copies and other amiodarone labels with other text. openFDA's own disclaimer says not to rely on it for decisions about medical care.
- Last checked: 2026-10-30
- Sources:
  1. Supports: openFDA drug label record for Pacerone (amiodarone hydrochloride tablets), Upsher-Smith label: indications, boxed warning and mechanism (Regulator, edition The openFDA drug label record for set id 4c4ec9b0-13a5-49a8-b57b-b3f64e4316a7 (manufacturer Upsher-Smith Laboratories, LLC; abbreviated application ANDA075135), returned on 2026-10-30. The label text is dated 2025-07-14 (effective\_time). Two repackager labels of Pacerone (Aphena, 2024-02-02; Bryant Ranch Prepack, 2025-11-05) and the labels of other amiodarone tablets and injections were listed and not used.) <https://api.fda.gov/drug/label.json?search=set_id:%224c4ec9b0-13a5-49a8-b57b-b3f64e4316a7%22&limit=1>
     Locator: results\[0\].indications\_and\_usage\[0\], 1, sentence 1, fragment 1 of 2. Retrieved 2026-10-30T19:46:30Z. Source state: Current. Version fingerprint: 634bb6709ac6c7617c0112368b9bc30cf00ea37e42a72ee3e2302b2ee7725e3b.
     How it applies: Indication, first part.
  2. Supports: openFDA drug label record for Pacerone (amiodarone hydrochloride tablets), Upsher-Smith label: indications, boxed warning and mechanism (Regulator, edition The openFDA drug label record for set id 4c4ec9b0-13a5-49a8-b57b-b3f64e4316a7 (manufacturer Upsher-Smith Laboratories, LLC; abbreviated application ANDA075135), returned on 2026-10-30. The label text is dated 2025-07-14 (effective\_time). Two repackager labels of Pacerone (Aphena, 2024-02-02; Bryant Ranch Prepack, 2025-11-05) and the labels of other amiodarone tablets and injections were listed and not used.) <https://api.fda.gov/drug/label.json?search=set_id:%224c4ec9b0-13a5-49a8-b57b-b3f64e4316a7%22&limit=1>
     Locator: results\[0\].indications\_and\_usage\[0\], 1, sentence 1, fragment 2 of 2. Retrieved 2026-10-30T19:46:30Z. Source state: Current. Version fingerprint: 634bb6709ac6c7617c0112368b9bc30cf00ea37e42a72ee3e2302b2ee7725e3b.
     How it applies: Indication, second part: adults and the condition on prior therapy.
  3. Supports: openFDA drug label record for Pacerone (amiodarone hydrochloride tablets), Upsher-Smith label: indications, boxed warning and mechanism (Regulator, edition The openFDA drug label record for set id 4c4ec9b0-13a5-49a8-b57b-b3f64e4316a7 (manufacturer Upsher-Smith Laboratories, LLC; abbreviated application ANDA075135), returned on 2026-10-30. The label text is dated 2025-07-14 (effective\_time). Two repackager labels of Pacerone (Aphena, 2024-02-02; Bryant Ranch Prepack, 2025-11-05) and the labels of other amiodarone tablets and injections were listed and not used.) <https://api.fda.gov/drug/label.json?search=set_id:%224c4ec9b0-13a5-49a8-b57b-b3f64e4316a7%22&limit=1>
     Locator: results\[0\].indications\_and\_usage\[0\], 1, highlights, item 1. Retrieved 2026-10-30T19:46:30Z. Source state: Current. Version fingerprint: 634bb6709ac6c7617c0112368b9bc30cf00ea37e42a72ee3e2302b2ee7725e3b.
     How it applies: Highlights line: ventricular fibrillation.
  4. Supports: openFDA drug label record for Pacerone (amiodarone hydrochloride tablets), Upsher-Smith label: indications, boxed warning and mechanism (Regulator, edition The openFDA drug label record for set id 4c4ec9b0-13a5-49a8-b57b-b3f64e4316a7 (manufacturer Upsher-Smith Laboratories, LLC; abbreviated application ANDA075135), returned on 2026-10-30. The label text is dated 2025-07-14 (effective\_time). Two repackager labels of Pacerone (Aphena, 2024-02-02; Bryant Ranch Prepack, 2025-11-05) and the labels of other amiodarone tablets and injections were listed and not used.) <https://api.fda.gov/drug/label.json?search=set_id:%224c4ec9b0-13a5-49a8-b57b-b3f64e4316a7%22&limit=1>
     Locator: results\[0\].indications\_and\_usage\[0\], 1, highlights, item 2. Retrieved 2026-10-30T19:46:30Z. Source state: Current. Version fingerprint: 634bb6709ac6c7617c0112368b9bc30cf00ea37e42a72ee3e2302b2ee7725e3b.
     How it applies: Highlights line: ventricular tachycardia.
  5. Supports: openFDA drug label record for Pacerone (amiodarone hydrochloride tablets), Upsher-Smith label: indications, boxed warning and mechanism (Regulator, edition The openFDA drug label record for set id 4c4ec9b0-13a5-49a8-b57b-b3f64e4316a7 (manufacturer Upsher-Smith Laboratories, LLC; abbreviated application ANDA075135), returned on 2026-10-30. The label text is dated 2025-07-14 (effective\_time). Two repackager labels of Pacerone (Aphena, 2024-02-02; Bryant Ranch Prepack, 2025-11-05) and the labels of other amiodarone tablets and injections were listed and not used.) <https://api.fda.gov/drug/label.json?search=set_id:%224c4ec9b0-13a5-49a8-b57b-b3f64e4316a7%22&limit=1>
     Locator: results\[0\].boxed\_warning\[0\], title. Retrieved 2026-10-30T19:46:30Z. Source state: Current. Version fingerprint: 634bb6709ac6c7617c0112368b9bc30cf00ea37e42a72ee3e2302b2ee7725e3b.
     How it applies: Title of the boxed warning.
  6. Supports: openFDA drug label record for Pacerone (amiodarone hydrochloride tablets), Upsher-Smith label: indications, boxed warning and mechanism (Regulator, edition The openFDA drug label record for set id 4c4ec9b0-13a5-49a8-b57b-b3f64e4316a7 (manufacturer Upsher-Smith Laboratories, LLC; abbreviated application ANDA075135), returned on 2026-10-30. The label text is dated 2025-07-14 (effective\_time). Two repackager labels of Pacerone (Aphena, 2024-02-02; Bryant Ranch Prepack, 2025-11-05) and the labels of other amiodarone tablets and injections were listed and not used.) <https://api.fda.gov/drug/label.json?search=set_id:%224c4ec9b0-13a5-49a8-b57b-b3f64e4316a7%22&limit=1>
     Locator: results\[0\].boxed\_warning\[0\], sentence 1. Retrieved 2026-10-30T19:46:30Z. Source state: Current. Version fingerprint: 634bb6709ac6c7617c0112368b9bc30cf00ea37e42a72ee3e2302b2ee7725e3b.
     How it applies: First sentence of the boxed warning.
  7. Supports: openFDA drug label record for Pacerone (amiodarone hydrochloride tablets), Upsher-Smith label: indications, boxed warning and mechanism (Regulator, edition The openFDA drug label record for set id 4c4ec9b0-13a5-49a8-b57b-b3f64e4316a7 (manufacturer Upsher-Smith Laboratories, LLC; abbreviated application ANDA075135), returned on 2026-10-30. The label text is dated 2025-07-14 (effective\_time). Two repackager labels of Pacerone (Aphena, 2024-02-02; Bryant Ranch Prepack, 2025-11-05) and the labels of other amiodarone tablets and injections were listed and not used.) <https://api.fda.gov/drug/label.json?search=set_id:%224c4ec9b0-13a5-49a8-b57b-b3f64e4316a7%22&limit=1>
     Locator: results\[0\].boxed\_warning\[0\], pulmonary. Retrieved 2026-10-30T19:46:30Z. Source state: Current. Version fingerprint: 634bb6709ac6c7617c0112368b9bc30cf00ea37e42a72ee3e2302b2ee7725e3b.
     How it applies: Pulmonary toxicity statement in the boxed warning.
  8. Supports: openFDA drug label record for Pacerone (amiodarone hydrochloride tablets), Upsher-Smith label: indications, boxed warning and mechanism (Regulator, edition The openFDA drug label record for set id 4c4ec9b0-13a5-49a8-b57b-b3f64e4316a7 (manufacturer Upsher-Smith Laboratories, LLC; abbreviated application ANDA075135), returned on 2026-10-30. The label text is dated 2025-07-14 (effective\_time). Two repackager labels of Pacerone (Aphena, 2024-02-02; Bryant Ranch Prepack, 2025-11-05) and the labels of other amiodarone tablets and injections were listed and not used.) <https://api.fda.gov/drug/label.json?search=set_id:%224c4ec9b0-13a5-49a8-b57b-b3f64e4316a7%22&limit=1>
     Locator: results\[0\].boxed\_warning\[0\], hepatic. Retrieved 2026-10-30T19:46:30Z. Source state: Current. Version fingerprint: 634bb6709ac6c7617c0112368b9bc30cf00ea37e42a72ee3e2302b2ee7725e3b.
     How it applies: Liver toxicity statement in the boxed warning (the label spells the word hepatoxicity).
  9. Supports: openFDA drug label record for Pacerone (amiodarone hydrochloride tablets), Upsher-Smith label: indications, boxed warning and mechanism (Regulator, edition The openFDA drug label record for set id 4c4ec9b0-13a5-49a8-b57b-b3f64e4316a7 (manufacturer Upsher-Smith Laboratories, LLC; abbreviated application ANDA075135), returned on 2026-10-30. The label text is dated 2025-07-14 (effective\_time). Two repackager labels of Pacerone (Aphena, 2024-02-02; Bryant Ranch Prepack, 2025-11-05) and the labels of other amiodarone tablets and injections were listed and not used.) <https://api.fda.gov/drug/label.json?search=set_id:%224c4ec9b0-13a5-49a8-b57b-b3f64e4316a7%22&limit=1>
     Locator: results\[0\].boxed\_warning\[0\], cardiac. Retrieved 2026-10-30T19:46:30Z. Source state: Current. Version fingerprint: 634bb6709ac6c7617c0112368b9bc30cf00ea37e42a72ee3e2302b2ee7725e3b.
     How it applies: Arrhythmia statement in the boxed warning.
  10. Background: openFDA drug label record for Pacerone (amiodarone hydrochloride tablets), Upsher-Smith label: indications, boxed warning and mechanism (Regulator, edition The openFDA drug label record for set id 4c4ec9b0-13a5-49a8-b57b-b3f64e4316a7 (manufacturer Upsher-Smith Laboratories, LLC; abbreviated application ANDA075135), returned on 2026-10-30. The label text is dated 2025-07-14 (effective\_time). Two repackager labels of Pacerone (Aphena, 2024-02-02; Bryant Ranch Prepack, 2025-11-05) and the labels of other amiodarone tablets and injections were listed and not used.) <https://api.fda.gov/drug/label.json?search=set_id:%224c4ec9b0-13a5-49a8-b57b-b3f64e4316a7%22&limit=1>
     Locator: results\[0\].effective\_time. Retrieved 2026-10-30T19:46:30Z. Source state: Current. Version fingerprint: 634bb6709ac6c7617c0112368b9bc30cf00ea37e42a72ee3e2302b2ee7725e3b.
     How it applies: Effective date of the label text read, 20250714.

## Connected pages

- The US tablet label lists recurrent hemodynamically unstable ventricular tachycardia: Ventricular tachycardia (`cardio:ventricular-tachycardia`) [a claim, not a settled fact; see claim `cardio:claim-fda-pacerone-label-indications` and its context]
- Filed under this front: Medicines (`cardio:front-medicines`)
- The FDA established pharmacologic class of amiodarone in RxClass is Antiarrhythmic: Antiarrhythmic drugs (`cardio:antiarrhythmic-drugs`)
- Related to: Dronedarone (`cardio:dronedarone`)

## Registry records

Records a program assembled from a public registry; no person wrote or checked them. They are counted here, not listed: the JSON record of this page lists each one in its relationships.

- 4 registry products
- 20 registry trials

## Provenance

Content hash: 51943232d4885d18223dda4bfc0b5b77b6908c70cb241d98c96621e942e9e28f
Last substantive edit: 2026-10-30
Evidence last checked: 2026-10-30
